Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2021.110564 http://scihub22266oqcxt.onion/10.1016/j.mehy.2021.110564 33823371!7985609!33823371     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2021 ; 150 (ä): 110564 Nephropedia Template TP {{tp|p=33823371|t=2021. Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19 |pdf=|usr=}}{{33823371}} gab.com Text Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33823371 #FOAvip We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease. Twit Text FOAVip Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33823371 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33823371 #FOAvip English Wikipedia <ref>{{Cite pmid|33823371}}</ref> Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19 #MMPMID33823371 Sanghavi DK; Titus A; Caulfield TR; David Freeman W Med Hypotheses 2021[May]; 150 (ä): 110564 PMID33823371show ga We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease. |*COVID-19 Drug Treatment[MESH] |Endothelin Receptor Antagonists/*therapeutic use[MESH] |Endothelins[MESH] |Endothelium, Vascular/*pathology[MESH] |Humans[MESH] |Receptors, Endothelin[MESH]Endotheliitis, endothelin, and endothelin receptor blockers in COVID-1(epmc).pdf DeepDyve Pubget Overpricing